{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022774","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.215543+00:00","generated_at":"2026-05-17T16:05:22.266074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M","bullets":["Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.","Thyroid test volume up 16% YoY; thyroid revenue $8.7M (+25% YoY) to record levels.","Gross margin 57% (65% ex one-time PancraGEN impact); adjusted EBITDA $0.4M vs $2.8M.","One-time charge $1.2M from PancraGEN reimbursement loss; company winding down test.","Preliminary July 2025 revenue $3.3M (+54% YoY); management sees Q3 improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022774","json":"https://secwatch.observer/filing/0001641172-25-022774.json","markdown":"https://secwatch.observer/filing/0001641172-25-022774.md","text":"https://secwatch.observer/filing/0001641172-25-022774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000164117225022774/0001641172-25-022774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000164117225022774/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:05:22.266074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}